Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake – Eli Lilly (NYSE:LLY)
Early Prescription Trends Show Slower Start For Lilly Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390…
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market – GoodRx Holdings (NASDAQ:GDRX), Novo Nordisk
• GoodRx Holdings shares are advancing steadily. What’s driving GDRX shares up? This move comes amid a growing…
Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report – Hims & Hers Health (NYSE:HIMS), Eli Lilly (NYSE:LLY)
Novo Nordisk AS (NYSE:NVO) and Hims & Hers Health Inc. (NYSE:HIMS) have reportedly ended their public feud, with…
Roche’s Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly – Roche Holding (OTC:RHHBY)
Genentech on Thursday shared topline results from the Phase 2 ZUPREME-1 trial evaluating petrelintide versus placebo in 493…
Benzinga Bulls And Bears: Rocket Lab, Kosmos Energy, Novo Nordisk — And Nvidia Fails To Boost Markets
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at…
Novo Nordisk’s Crash Has Created A Rare Valuation Gap – Novo Nordisk (NYSE:NVO)
But beneath the selloff, something unusual has emerged. Novo Nordisk is no longer priced like a hypergrowth AI-era…
Novo Nordisk Stock (NVO) Tumbles in ‘Worst Case Scenario’ – Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO)
Novo Nordisk AS (NYSE:NVO), once the darling of the pharmaceutical world, tumbled Monday as investors reacted to what…
Novo Nordisk Stock Hits 52-Week Low – Here’s Why – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) stock is plunging on Monday on disappointing headline data from its REDEFINE 4, an…
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs – Hims & Hers Health (NYSE:HIMS), Eli Lilly and Co (NYSE:LLY)
Novo Nordisk (NYSE:NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when…